Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: Treatment outcome and prognostic factors

Journal of Hepatology

Volumn 62, Issue 5, 2015, Pages 1112-1121

  Sohn, Won ^a   Paik, Yong Han ^a   Cho, Ju Yeon ^a   Lim, Ho Yeong ^a   Ahn, Jem Ma ^a   Sinn, Dong Hyun ^a   Gwak, Geum Youn ^a   Choi, Moon Seok ^a   Lee, Joon Hyeok ^a   Koh, Kwang Cheol ^a   Paik, Seung Woon ^a   Yoo, Byung Chul ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

Extrahepatic spread; Hepatocellular carcinoma; Sorafenib

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; SERUM ALBUMIN; SORAFENIB; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHILD PUGH SCORE; DISEASE COURSE; FEMALE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER METASTASIS; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERITONEUM METASTASIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR INVASION; UNSPECIFIED SIDE EFFECT; AGED; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; COMPLICATION; HEPATITIS B, CHRONIC; LIVER; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RADIOGRAPHY; RISK FACTOR; SOUTH KOREA; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84927788483     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.12.009     Document Type: Article

References (26)

1. H.B. El-Serag Hepatocellular carcinoma N Engl J Med 365 2011 1118 1127
2. J. Bruix, and M. Sherman Management of hepatocellular carcinoma Hepatology 42 2005 1208 1236
3. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma J Hepatol 56 2012 908 943
4. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
5. A.L. Cheng, Y.K. Kang, Z. Chen, C.J. Tsao, S. Qin, and J.S. Kim Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 2009 25 34
6. F. Pons, M. Varela, and J.M. Llovet Staging systems in hepatocellular carcinoma HPB 7 2005 35 41
7. M. Natsuizaka, T. Omura, T. Akaike, Y. Kuwata, K. Yamazaki, and T. Sato Clinical features of hepatocellular carcinoma with extrahepatic metastases J Gastroenterol Hepatol 20 2005 1781 1787
8. M. Kanda, R. Tateishi, H. Yoshida, T. Sato, R. Masuzaki, and T. Ohki Extrahepatic metastasis of hepatocellular carcinoma: incidence and risk factors Liver Int 28 2008 1256 1263
9. K. Uchino, R. Tateishi, S. Shiina, M. Kanda, R. Masuzaki, and Y. Kondo Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors Cancer 117 2011 4475 4483
10. R. Lencioni, M. Kudo, S.L. Ye, J.P. Bronowicki, X.P. Chen, and L. Dagher First interim analysis of the GIDEON (Global Investigation of therapeutic Decisions in hepatocellular carcinoma and of Its treatment with sorafeNib) non-interventional study Int J Clin Pract 66 2012 675 683
11. M. Iavarone, G. Cabibbo, F. Piscaglia, C. Zavaglia, A. Grieco, and E. Villa Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy Hepatology 54 2011 2055 2063
12. M.M. Oken, R.H. Creech, D.C. Tormey, J. Horton, T.E. Davis, and E.T. McFadden Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 1982 649 655
13. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, and R. Ford New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
14. J. Bruix, J.L. Raoul, M. Sherman, V. Mazzaferro, L. Bolondi, and A. Craxi Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial J Hepatol 57 2012 821 829
15. A.L. Cheng, Z. Guan, Z. Chen, C.J. Tsao, S. Qin, and J.S. Kim Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial Eur J Cancer 48 2012 1452 1465
16. T. Kawaoka, H. Aikata, E. Murakami, T. Nakahara, N. Naeshiro, and M. Tanaka Evaluation of the mRECIST and alpha-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib Oncology 83 2012 192 200
17. M. Pinter, W. Sieghart, F. Hucke, I. Graziadei, W. Vogel, and A. Maieron Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib Aliment Pharmacol Ther 34 2011 949 959
18. A. Hollebecque, S. Cattan, O. Romano, G. Sergent, A. Mourad, and A. Louvet Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score Aliment Pharmacol Ther 34 2011 1193 1201
19. T. Pressiani, C. Boni, L. Rimassa, R. Labianca, S. Fagiuoli, and S. Salvagni Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis Ann Oncol 24 2013 406 411
20. S.M. Jung, J.W. Jang, C.R. You, S.H. Yoo, J.H. Kwon, and S.H. Bae Role of intrahepatic tumor control in the prognosis of patients with hepatocellular carcinoma and extrahepatic metastases J Gastroenterol Hepatol 27 2012 684 689
21. M. Nakano, M. Tanaka, R. Kuromatsu, H. Nagamatsu, K. Sakata, and S. Matsugaki Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma Oncology 84 2013 108 114
22. T. Sonoda, T. Kanematsu, K. Takenaka, and K. Sugimachi Ruptured hepatocellular carcinoma evokes risk of implanted metastases J Surg Oncol 41 1989 183 186
23. M.S. Kwak, J.H. Lee, J.H. Yoon, S.J. Yu, E.J. Cho, and E.S. Jang Risk factors, clinical features, and prognosis of the hepatocellular carcinoma with peritoneal metastasis Dig Dis Sci 57 2012 813 819
24. C.Y. Wu, Y.J. Chen, H.J. Ho, Y.C. Hsu, K.N. Kuo, and M.S. Wu Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection JAMA 308 2012 1906 1914
25. J. Yin, N. Li, Y. Han, J. Xue, Y. Deng, and J. Shi Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study J Clin Oncol 31 2013 3647 3655
26. M. Reig, J. Rimola, F. Torres, A. Darnell, C. Rodriguez-Lope, and A. Forner Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design Hepatology 58 2013 2023 2031